Should Direct-Acting Antiviral Agents Replace the Standard of Care for Hepatitis C Infection?

For the 3.2 million people in the United States infected with the hepatitis C virus, disease management can be costly and debilitating. But are the new agents recently approved by the Food and Drug Administration (FDA) a better way to manage the disease? Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—What You Need to Know is a complimentary webinar hosted by Hayes, Inc. that will provide you with the latest information about the new management options being used to fight the disease. Reserve your seat to hear Erika M. Hedden, PhD, CMPP, Senior Research Analyst, summarize the current body of evidence surrounding these new treatments on Tuesday, September 23, 2014, at 1:00 pm ET.

“Hepatitis C is a complex and challenging disease to treat,” says Dr. Hedden. “And only about 5% or 6% of patients who have the disease are successfully treated using the current standard of care. The new direct-acting antivirals were developed with the intent to simplify treatment, improve response rates, and overcome some of the debilitating side effects patients experience with current treatments. The evidence is promising, but if we consider the limitations and gaps, it’s premature to consider these new agents to be the panacea for hepatitis C management. Understanding the available evidence is especially important given the cost burden of these new agents to the system.”

Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—What You Need to Know is open to all healthcare professionals interested in learning about the changing treatment landscape of hepatitis C. This includes physicians, nurses, pharmacists, imaging and surgical technologists, physician assistants, medical assistants, case managers, hospital and healthcare administrators, medical policy specialists, health educators, community health and outreach healthcare workers, medical support staff, and other interested individuals.

Continuing Medical Education (CME) and Continuing Education (CE) credits will be available to participants who attend the live webinar. In addition, the webinar will be recorded and CME and CE credits will be available through November 24, 2014, to those who listen to the recording.

About Hayes
Hayes, Inc., an internationally recognized leader in health technology research and consulting, is dedicated to the delivery of high-quality healthcare and improved outcomes through the integration of evidence into decision making and policy development. The unbiased information and comparative-effectiveness analyses we provide enable evidence-based decisions about acquiring, managing, and paying for health technologies. Our worldwide clients include hospitals, healthcare systems, government agencies, health plans, and employers. Hayes, Inc. is a certified woman-owned small business (WOSB).